Characterization of uterine leiomyomas by whole-genome sequencing. - Wikidata - wikimedia - TriplyDB

Characterization of uterine leiomyomas by whole-genome sequencing.

Characterization of uterine leiomyomas by whole-genome sequencing.

http://www.wikidata.org/entity/Q50935563

about

Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management Mediator kinase module and human tumorigenesis A novel human leiomyoma tissue derived matrix for cell culture studies.Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.5-Hydroxymethylcytosine promotes proliferation of human uterine leiomyoma: a biological link to a new epigenetic modification in benign tumors.Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry.MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.Cytogenetically normal uterine leiomyomas without MED12-mutations - a source to identify unknown mechanisms of the development of uterine smooth muscle tumors.Follow-up to genome-wide linkage and admixture mapping studies implicates components of the extracellular matrix in susceptibility to and size of uterine fibroids.MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?Tissue-specific stem cells in the myometrium and tumor-initiating cells in leiomyoma.Evaluation of GWAS candidate susceptibility loci for uterine leiomyoma in the multi-ethnic NIEHS uterine fibroid study.Chromothripsis and Kataegis Induced by Telomere Crisis Fine mapping of the uterine leiomyoma locus on 1q43 close to a lncRNA in the RGS7-FH interval MED12 exon 2 mutations in phyllodes tumors of the breast Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.Med12 gain-of-function mutation causes leiomyomas and genomic instability.Genomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels.Fibroids: Genotype and Phenotype.Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma History of uterine leiomyoma and risk of endometrial cancer in black women.COL4A6 is dispensable for autosomal recessive Alport syndrome.MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.MicroRNA-15b regulates reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in human uterine leiomyoma.Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements The Genetics of Infertility: Current Status of the Field.Identification of complex genomic rearrangements in cancers using CouGaR Frequent L1 retrotranspositions originating from TTC28 in colorectal cancer.Molecular pathological analysis of sarcomas using paraffin-embedded tissue: current limitations and future possibilities.Genetic alterations in uterine fibroids - a new direction for pharmacological intervention?Malignant tumors of the uterine corpus: molecular background of their origin.

P2860

Q24567733-94C46E1D-9538-4A13-9C60-41C67E09D6D8 Q26799918-3C82B3B4-72BE-4F49-A696-B64C7189D401 Q26800203-40D8F27B-C74E-4C06-BD61-107F6EDFA9D3 Q27311417-65DFCFE2-3D88-4A7F-82EF-FA9BA3EA3360 Q28243075-93833964-4648-4731-ABA2-8BFD03C30B3D Q28260148-6603C206-E339-42AC-A76B-8D85CAC6A9F0 Q31038292-32EB3005-324A-4AE6-AB49-D36844078946 Q33438485-34E7C125-B442-44DB-8E0A-D6B4DA310DBE Q33555242-65A064C2-BC8A-4516-9ACB-0A726E8C1FE6 Q33570198-BC18B7D1-F2FE-4386-91E7-5950BDC12AEB Q33682500-FAEF5A37-CF9A-4535-A48D-0B7B01D31972 Q33698048-F3F2B76B-0C85-432E-904C-0159B5353644 Q33721856-1489BBFC-4626-4220-AF7D-73CBC19298C2 Q33844725-C494BF72-2754-4A40-A0A9-B663D2C1EC07 Q34437666-234DAF77-51E2-4E10-8995-2135F6EF798C Q34686027-DDF97BC5-B475-463F-A249-F4E2BE98D47F Q35039819-6DBCF438-9E6E-4A78-AE7A-FCBFE51A1E95 Q35140553-54331F42-9BF5-4B15-B3E5-0F1C3400C3B9 Q35617315-CEE0B4D3-3C36-4251-8CE2-578B49345851 Q35848664-C7C55164-675B-4B0F-AF9F-36550D25B7F4 Q35873764-2574FE2B-3A2E-4BB5-98BD-1BFC217A2179 Q35921937-837A56D3-C480-4921-A776-58B97951C75C Q35928937-5BF6F96B-0909-418D-84FE-0DEA3E9F593D Q35944399-2A2BB60F-C814-4052-9A99-CE6C8BE53904 Q36040538-07AFE91D-C8E7-490F-99BE-CF3E5C4FE569 Q36448418-0310C0B4-2F9D-4AF1-914C-547DFE28E83C Q36522634-C376B7DC-CD6C-4662-A0A3-685DBB7E90B2 Q36559251-F707F4B4-15F5-4887-BA66-0C8945E8A7E8 Q36703320-135CDCC9-BDC4-4C4E-96FB-6A8AC6A511B5 Q37063978-C0E29C60-8AF9-4D27-B5AA-7896AF3C6C9F Q37174047-449B7D6E-A88E-4880-8B27-126E91A4A476 Q37182392-9349A43A-7C8E-4CF3-AEFF-723870E83D81 Q37281509-B23FD0FB-5020-436C-B3CC-A269A132A93A Q37388875-77325136-D962-480D-8BA3-FDD649E9D3B4 Q37450892-A7789820-ADD9-4877-A212-DE1B4DAD2B23 Q37548472-B257261F-A867-41DE-B5F5-E5F34BB18BAB Q37718433-B740A103-999C-4030-A3A6-E91F0DFF7CBB Q38150909-76484743-C865-41D1-A490-5210EA9A86D1 Q38570659-4D694692-4504-4B98-B748-1E670A63A9F3 Q38573869-94B89073-0DCE-474C-9985-DF424EA17CAF

P2860

Characterization of uterine leiomyomas by whole-genome sequencing.

http://www.wikidata.org/entity/Q50935563

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Characterization of uterine leiomyomas by whole-genome sequencing.

@en

Characterization of uterine leiomyomas by whole-genome sequencing.

@nl

type

label

Characterization of uterine leiomyomas by whole-genome sequencing.

@en

Characterization of uterine leiomyomas by whole-genome sequencing.

@nl

prefLabel

Characterization of uterine leiomyomas by whole-genome sequencing.

@en

Characterization of uterine leiomyomas by whole-genome sequencing.

@nl

P1433

Q50935563-2154C78E-C567-4516-A708-AE7BC63557A4

P1476

Q50935563-5B96CDC6-680C-45D3-8797-8F19A42528C1

P2093

Q50935563-19727B6E-07BF-400B-80CF-8EC158E40ED5

Q50935563-3BF9CC68-3A29-4824-BD68-5DE224E5CCAA

Q50935563-476E16E6-A650-4F44-9694-964AD604AA18

Q50935563-6769D349-1784-4E97-AD21-61FC3097F69F

Q50935563-7FD8397F-80D6-44BA-980A-56F0455A9CB6

Q50935563-98ED55DD-65A3-45E1-97F2-5BF6D7770226

Q50935563-B57F8697-6508-4CA9-BF78-9C3B618FD042

Q50935563-B7684F9E-E8C7-4346-80AA-34AA7AC0CC00

Q50935563-BD5BD850-FBC0-4DE6-B2FC-C6876CDD6868

Q50935563-CE5C7025-3C02-4462-80F5-CDF54E5B3193

P304

Q50935563-9289EAF9-1FA7-4C81-B408-0C7840FE0FCE

P31

Q50935563-08618155-F477-416B-8E9D-4504621754B7

P356

Q50935563-637EB098-D6D6-49F5-96A7-45A63CE68598

P407

Q50935563-D4ADC40F-B2B1-4380-8178-9389A0C30888

P433

Q50935563-80311F7E-4215-4CCC-90C2-847E588852F9

P478

Q50935563-DD62BA06-FF3D-462C-8197-477661A741DD

P50

Q50935563-2B61D0E4-141D-48A8-ADB2-6AEB25CF8FE3

Q50935563-5970278A-13ED-4B3D-9ACC-6C90FA6CD1A9

Q50935563-81294878-6CCB-46AB-9B9A-D1AE5A2818BA

Q50935563-8B143B54-3819-480D-8595-6A63ABE2E3A0

Q50935563-B5341CC6-2B2C-43B6-8A9B-3CEAB5A17527

P577

Q50935563-37A51E8B-8FC3-432C-8949-4AA6637DC032

P698

Q50935563-B0BC23F8-92F8-4E84-AD37-6EE264971E8D

P356

P1433

The New England Journal of Medicine

P1476

Characterization of uterine leiomyomas by whole-genome sequencing

@en

P2093

Eevi Kaasinen

http://www.w3.org/2001/XMLSchema#string

Heikki Ristolainen

http://www.w3.org/2001/XMLSchema#string

Jari Sjöberg

http://www.w3.org/2001/XMLSchema#string

Kati Kämpjärvi

http://www.w3.org/2001/XMLSchema#string

Massimiliano Gentile

http://www.w3.org/2001/XMLSchema#string

Miika Mehine

http://www.w3.org/2001/XMLSchema#string

Outi Kilpivaara

http://www.w3.org/2001/XMLSchema#string

Pia Vahteristo

http://www.w3.org/2001/XMLSchema#string

Ralf Bützow

http://www.w3.org/2001/XMLSchema#string

Riku Katainen

http://www.w3.org/2001/XMLSchema#string

P304

43-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1302736

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Hanna-Riikka Heinonen

P577

2013-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23738515

http://www.w3.org/2001/XMLSchema#string